title: Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft.
authors.forename: C
authors.initials: C
authors.lastname: Rose
authors.forename: S
authors.initials: S
authors.lastname: Dupire
authors.forename: C
authors.initials: C
authors.lastname: Roche-Lestienne
authors.forename: N
authors.initials: N
authors.lastname: Grardel
authors.forename: E
authors.initials: E
authors.lastname: Bourgeois
authors.forename: N
authors.initials: N
authors.lastname: Cambier
authors.forename: C
authors.initials: C
authors.lastname: Preudhomme
mesh_terms: D000328:Adult; D001549:Benzamides; D036101:Cord Blood Stem Cell Transplantation; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy* / Q000235:genetics / Q000628:therapy; D000068877:Imatinib Mesylate; D007938:Leukemia / Q000188:drug therapy* / Q000235:genetics / Q000628:therapy; D008297:Male; D025202:Molecular Diagnostic Techniques; D010879:Piperazines / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction; D011743:Pyrimidines / Q000627:therapeutic use*; D012008:Recurrence; D012074:Remission Induction / Q000379:methods; D014184:Transplantation, Homologous
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate